TABLE 2.
Spectra of activity (UM − Vm) against VREa
| Compound | VREfm (clinical)b,c | VREfm (BAA-2317) | VREfm (BAA-2318) | VREfm (BAA-2365) | VREfa (49532) | VREfa (49533) | VREfa (51575) | VREfa (700802) |
|---|---|---|---|---|---|---|---|---|
| Rifampin | 0.10 | NAd | 0.39 | 1.6 | 6.25 | 6.25 | 6.25 | 6.25 |
| Retapamulin | 0.20 | 9.8 × 10−2 | 9.8 × 10−2 | NA | NA | NA | NA | NA |
| Rifabutin | 0.20 | NA | 0.78 | 3.1 | 25 | 25 | 25 | 25 |
| Rifapentine | 0.20 | NA | 1.6 | 3.1 | 6.25 | 6.25 | 6.25 | 12.5 |
| Rifaximin | 0.39 | 50 | 25 | 1.6 | 1.6 | 1.6 | 3.1 | 1.6 |
| Valnemulin | 0.39 | 0.39 | 0.39 | NA | NA | NA | NA | NA |
| Gemcitabine | 0.78 | 0.39 | 2.4 × 10−2 | 0.78 | 1.6 | 1.6 | 0.78 | 3.1 |
a
MICs are in μM.
b
Values from Table 1.
c
The VREfm used in this study was a clinical isolate from the University of Missouri-Kansas City School of Medicine. For other strains, the American Type Culture Collection (ATCC) catalog numbers are given in parentheses.
d
NA, not active at 50 μM, the highest concentration used in these MIC determinations.